RPh MBA - Fresh Tracks CoFounder Chairman
| FRTXDelisted Stock | USD 0.78 0.09 10.34% |
Insider
RPh MBA is CoFounder Chairman of Fresh Tracks Therapeutics
| Age | 65 |
| Phone | 720 505 4755 |
| Web | https://www.frtx.com |
Fresh Tracks Management Efficiency
The company has return on total asset (ROA) of (0.4227) % which means that it has lost $0.4227 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8103) %, meaning that it created substantial loss on money invested by shareholders. Fresh Tracks' management efficiency ratios could be used to measure how well Fresh Tracks manages its routine affairs as well as how well it operates its assets and liabilities.Fresh Tracks Therapeutics currently holds 49 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Fresh Tracks Therapeutics has a current ratio of 6.23, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Fresh Tracks until it has trouble settling it off, either with new capital or with free cash flow. So, Fresh Tracks' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Fresh Tracks Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Fresh to invest in growth at high rates of return. When we think about Fresh Tracks' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Mark Dudley | Instil Bio | N/A | |
| Julie Person | Third Harmonic Bio | 50 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Gary Hattersley | Nuvation Bio | 57 | |
| Susan Kahlert | Senti Biosciences | N/A | |
| Karl MD | Achilles Therapeutics PLC | 57 | |
| Stacy Markel | Nuvation Bio | 59 | |
| Eddie Sullivan | SAB Biotherapeutics | 58 | |
| Robert Coutts | Achilles Therapeutics PLC | 40 | |
| Iraj Ali | Achilles Therapeutics PLC | 49 | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| MD MBA | Kiora Pharmaceuticals | 50 | |
| Kathryn Falberg | Nuvation Bio | 60 | |
| Uri MD | Assembly Biosciences | 52 | |
| Sandeep MD | Instil Bio | 55 | |
| Edward MD | Third Harmonic Bio | 51 | |
| John CPA | Unicycive Therapeutics | 62 | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
| MD FACP | NextCure | 71 | |
| W Vernon | Nuvation Bio | 65 | |
| Lieping MD | NextCure | 67 | |
Management Performance
| Return On Equity | -0.81 | ||||
| Return On Asset | -0.42 |
Fresh Tracks Therapeutics Leadership Team
Elected by the shareholders, the Fresh Tracks' board of directors comprises two types of representatives: Fresh Tracks inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fresh. The board's role is to monitor Fresh Tracks' management team and ensure that shareholders' interests are well served. Fresh Tracks' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fresh Tracks' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Albert II, CFO Officer | ||
| Andrew Sklawer, Pres CoFounder | ||
| Nancy Seretta, VP Operations | ||
| PM MBA, VP Operations | ||
| Gary Walker, Chief Officer | ||
| Attorney Brown, CEO Director | ||
| David JD, G Officer | ||
| RPh MBA, CoFounder Chairman | ||
| Sue Fattor, Head Resource | ||
| MBA MS, Chief COO |
Fresh Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Fresh Tracks a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.81 | ||||
| Return On Asset | -0.42 | ||||
| Profit Margin | (0.89) % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | (4.04 M) | ||||
| Shares Outstanding | 5.97 M | ||||
| Shares Owned By Insiders | 11.62 % | ||||
| Shares Owned By Institutions | 8.96 % | ||||
| Number Of Shares Shorted | 50.18 K | ||||
| Price To Book | 0.45 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in Fresh Pink Sheet
If you are still planning to invest in Fresh Tracks Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fresh Tracks' history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Global Correlations Find global opportunities by holding instruments from different markets |